Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors

2022194 citationsJournal Articlehybrid Open Access

Authors

George D. Demetri · Dana-Farber Cancer Institute

Filippo De Braud · University of Milan

Alexander Drilon · Memorial Sloan Kettering Cancer Center

Salvatore Siena · University of Milan

Manish R. Patel · University of Minnesota

Byoung Chul Cho · National Cancer Center

Stephen V. Liu · Georgetown University

Myung-Ju Ahn

Abstract

With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.

Topics & Keywords

Lung Cancer Treatments and Mutations Brain Metastases and Treatment Melanoma and MAPK Pathways

Publication Details

Published in: Clinical Cancer Research

Volume 28, Issue 7, pp. 1302-1312

DOI: 10.1158/1078-0432.ccr-21-3597

Field-Weighted Citation Impact: 27.56

Command Palette

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors

Authors

Abstract

Topics & Keywords

Publication Details